NASDAQ:SLGL

Sol-gel Technologies Stock Insider Trading

Healthcare > Biotechnology

Buy SLGL

*Your capital is at risk

$71.50

-2.23 (-3.02%)

At Close: Jun 03, 2026

Sol-Gel Technologies Stock Insider Power

Based on the 64 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 432.46K and sold 0 SLGL shares in the last 64 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 64 transactions)	100.00
● Buy	432.46K shares
● Sell	0 shares
100% Buy Activity Weak Positive Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 23, 2025 Buy	Ordinary Shares, par value NIS 1.00 per share. P-Purchase	Opaleye Management Inc. 10 Percent Owner	10% Owner	260 Value: $10.8K
Dec 22, 2025 Buy	Ordinary Shares, par value NIS 1.00 per share. P-Purchase	Opaleye Management Inc. 10 Percent Owner	10% Owner	1 019 Value: $41.9K
Dec 17, 2025 Buy	Ordinary Shares, par value NIS 1.00 per share. P-Purchase	Opaleye Management Inc. 10 Percent Owner	10% Owner	2 735 Value: $110.4K
Dec 12, 2025 Buy	Ordinary Shares, par value NIS 1.00 per share. P-Purchase	Opaleye Management Inc. 10 Percent Owner	10% Owner	87 Value: $3K
Dec 08, 2025 Buy	Ordinary Shares, par value NIS 1.00 per share. P-Purchase	Opaleye Management Inc. 10 Percent Owner	10% Owner	300 Value: $11.9K
Dec 05, 2025 Buy	Ordinary Shares, par value NIS 1.00 per share. P-Purchase	Opaleye Management Inc. 10 Percent Owner	10% Owner	444 Value: $17.5K
Dec 03, 2025 Buy	Ordinary Shares, par value NIS 1.00 per share. P-Purchase	Opaleye Management Inc. 10 Percent Owner	10% Owner	2 524 Value: $95.4K
Dec 01, 2025 Buy	Ordinary Shares, par value NIS 1.00 per share. P-Purchase	Opaleye Management Inc. 10 Percent Owner	10% Owner	4 340 Value: $162.2K
Nov 26, 2025 Buy	Ordinary Shares, par value NIS 1.00 per share. P-Purchase	Opaleye Management Inc. 10 Percent Owner	10% Owner	943 Value: $37.7K
Nov 24, 2025 Buy	Ordinary Shares, par value NIS 1.00 per share. P-Purchase	Opaleye Management Inc. 10 Percent Owner	10% Owner	6 Value: $213
Nov 20, 2025 Buy	Ordinary Shares, par value NIS 1.00 per share. P-Purchase	Opaleye Management Inc. 10 Percent Owner	10% Owner	5 784 Value: $207.2K
Nov 13, 2025 Buy	Ordinary Shares, par value NIS 1.00 per share	Opaleye Management Inc. 10 Percent Owner	10% Owner	0 Value: $0
Nov 13, 2025 Buy	Ordinary Shares, par value NIS 1.00 per share	Opaleye Management Inc. 10 Percent Owner	10% Owner	0 Value: $0
Jan 07, 2023 Buy	Warrants (right to buy)	Arkin Moshe Chairman Of Board And CEO	CEO / President	200 000 Value: $11.7M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT SOL-GEL TECHNOLOGIES LTD.

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream ...

Read Full Profile Here